Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3U7SZ)

• Drug Name: Romiplostim Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Thrombocytopenia	3B64	Approved	[1]
Multiple myeloma	2A83	Phase 2	[2]
Myelodysplastic syndrome	2A37	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 5329098
  ChEBI ID: CHEBI:91083
  CAS Number: CAS 194413-58-6
  TTD Drug ID: DM3U7SZ

Molecule-Related Drug Atlas

Drug(s) Targeting Thrombopoietin receptor (MPL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eltrombopag	DMOGFIX	Thrombocytopenia	3B64	Approved	[14]
Lusutrombopag	DMH6IKO	Thrombocytopenia	3B64	Approved	[15]
AS-1670542	DMV05SW	Thrombocytopenia	3B64	Approved	[16]
LGD-4665	DM9T8A2	Immune thrombocytopenic purpura	3B64.13	Phase 2	[14]
BVI-007	DM43GPX	Myocardial infarction	BA41-BA43	Phase 1	[16]
NIP-004	DM0PYEQ	Thrombocytopenia	3B64	Phase 1	[17]
RhTPO	DMCV0BZ	Idiopathic thrombocytopenic purpura	3B64.10	Discontinued in Phase 3	[14]
Totrombopag	DM6SUDC	Thrombocytopenia	3B64	Discontinued in Phase 1	[18]
Promegapoietin	DMS4FG0	Bone marrow transplantation	QB63.6	Terminated	[19]
		N. A.	N. A.		[16]

Drug(s) Targeting Aryl hydrocarbon receptor (AHR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tapinarof	DMRPI2Q	Plaque psoriasis	EA90.0	Approved	[20]
RVT-505	DM3C9F8	Atopic dermatitis	EA80	Phase 2	[21]
IK-175	DMDU54Y	Urothelial carcinoma	2C92.0	Phase 1	[22]
BAY 2416964	DMD9N12	Solid tumour/cancer	2A00-2F9Z	Phase 1	[23]
AT-177	DMJ02RH	Ulcerative colitis	DD71	Clinical trial	[24]
CB7993113	DMJUQ6E	Solid tumour/cancer	2A00-2F9Z	Preclinical	[25]
2-(1H-indole-3,-carbonyl)-thiazole-4-carboxylic acid methyl ester	DMIS1G7	Glioma	2A00.0	Preclinical	[26]
6-Formylindolo[3,2-b]carbazole	DMN84RM	Dermatitis	EA80-EA89	Investigative	[27]
CH-223191	DMMJZYC	Solid tumour/cancer	2A00-2F9Z	Investigative	[28]

Drug(s) Targeting Fibroblast growth factor receptor 1 (FGFR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[29]
Pemigatinib	DM819JF	Cholangiocarcinoma	2C12.10	Approved	[30]
Infigratinib	DMNKBEC	Cholangiocarcinoma	2C12.10	Approved	[31]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[32]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[33]
ARQ-087	DM02BVQ	Intrahepatic cholangiocarcinoma	2C12.10	Phase 3	[34]
AZD4547	DM3827C	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[35]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[36]
AM-001	DMGVQI8	Actinic keratosis	EK90.0	Phase 2	[37]
FGF-1	DMXMC8I	Coronary heart disease	BA80.Z	Phase 2	[38]

Drug(s) Targeting Platelet-derived growth factor receptor alpha (PDGFRA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ripretinib	DM958QB	Gastrointestinal stromal tumour	2B5B	Approved	[39]
Olaratumab	DMNYOIX	Soft tissue sarcoma	2B57	Approved	[40]
Avapritinib	DMK2GZX	Gastrointestinal stromal tumour	2B5B	Approved	[41]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[32]
CP-868596	DMZIM37	Gastrointestinal cancer	2C11	Phase 3	[42]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[43]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[44]
MP470	DMELUAK	Solid tumour/cancer	2A00-2F9Z	Phase 2	[45]
MEDI-575	DMI9WVM	Glioblastoma multiforme	2A00.0	Phase 2	[46]
Pyridine derivative 18	DMBZMYT	N. A.	N. A.	Patented	[47]

Drug(s) Targeting Tyrosine-protein kinase Kit (KIT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[48]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[49]
Regorafenib	DMHSY1I	Gastrointestinal stromal tumour	2B5B	Approved	[50]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[50]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[51]
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour	2F7B	Approved	[52]
Ripretinib	DM958QB	Gastrointestinal stromal tumour	2B5B	Approved	[39]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[43]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[44]
MP470	DMELUAK	Solid tumour/cancer	2A00-2F9Z	Phase 2	[45]

Drug(s) Targeting Platelet-derived growth factor receptor beta (PDGFRB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[49]
Becaplermin	DM1R5X4	Diabetic complication	5A2Y	Approved	[19]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[32]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[43]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[44]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[53]
SNN-0031	DM2X3BR	Brain injury	NA07.Z	Phase 1/2	[54]
TAK-593	DMNFZOT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[55]
Pyridine derivative 18	DMBZMYT	N. A.	N. A.	Patented	[47]
PMID25656651-Compound-21a	DMCKAON	N. A.	N. A.	Patented	[56]

Drug(s) Targeting Proto-oncogene c-Ret (RET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Regorafenib	DMHSY1I	Gastrointestinal stromal tumour	2B5B	Approved	[50]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[50]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[48]
Selpercatinib	DMZR15V	Non-small-cell lung cancer	2C25.Y	Approved	[57]
Pralsetinib	DMWU0I2	Non-small-cell lung cancer	2C25.Y	Approved	[58]
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[59]
CEP-32496	DMAO04B	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[36]
TPX-0046	DMIVE67	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[60]
GSK3179106	DM2KCIP	Inflammatory bowel disease	DD72	Phase 1	[61]
BOS172738	DM9L0D8	Solid tumour/cancer	2A00-2F9Z	Phase 1	[62]

Drug(s) Targeting VEGFR1 messenger RNA (VEGFR1 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VATALANIB	DMY0UEQ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[63]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[53]
Sirna-027	DMZTQD8	Exudative age-related macular degeneration	9B78.3Z	Phase 1/2	[64]
PMID22765894C8h	DMH5RFU	Discovery agent	N.A.	Investigative	[65]
2-(1H-indazol-3-yl)-1H-benzo[d]imidazole	DM0CSH8	Discovery agent	N.A.	Investigative	[66]
AAL-993	DM35RFH	Discovery agent	N.A.	Investigative	[63]
PMID17935989C25	DML8ZBR	Discovery agent	N.A.	Investigative	[67]
2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile	DMX6QMT	Discovery agent	N.A.	Investigative	[68]
4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide	DMI3OR9	Discovery agent	N.A.	Investigative	[69]
(2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine	DMQWD75	Discovery agent	N.A.	Investigative	[68]

Drug(s) Targeting Vascular endothelial growth factor receptor 2 (KDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[49]
Regorafenib	DMHSY1I	Gastrointestinal stromal tumour	2B5B	Approved	[50]
Sunitinib	DMCBJSR	Acute undifferentiated leukemia		Approved	[70]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[71]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[48]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[51]
Fruquintinib	DMHOSCQ	Colorectal cancer	2B91.Z	Approved	[72]
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[73]
Tivozanib	DMUKC5L	Renal cell carcinoma	2C90	Approved	[74]
Lenvatinib	DMB1IU4	Thyroid cancer	2D10	Approved	[75]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[130]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[131]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[132]
Haloperidol	DM96SE0	Delirium		Approved	[133]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[134]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[135]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[133]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[136]
Orlistat	DMRJSP8	Obesity	5B81	Approved	[137]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[138]

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[76]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[77]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[78]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[79]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[80]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[81]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[82]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[83]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[84]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[85]

Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[86]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[86]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[86]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[87]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[88]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[89]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[90]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[91]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[92]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[93]

Drug(s) Affected By Interleukin-1 beta (IL1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[94]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[95]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[96]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[97]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[98]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[97]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[99]
Selenium	DM25CGV	N. A.	N. A.	Approved	[100]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[101]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[102]

Drug(s) Affected By High mobility group protein B1 (HMGB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[103]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[96]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[104]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[105]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[106]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[107]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[107]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[108]
Dihydroartemisinin	DMBXVMZ	Malaria	1F40-1F45	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[110]

Drug(s) Affected By Ribosomal protein S6 kinase beta-1 (RPS6KB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[111]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[112]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[113]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[114]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[115]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[116]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[117]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[118]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[119]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[120]

Drug(s) Affected By RAC-alpha serine/threonine-protein kinase (AKT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[121]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[122]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[123]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[124]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[125]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[114]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[126]
Selenium	DM25CGV	N. A.	N. A.	Approved	[127]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[128]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[129]

Drug(s) Affected By Receptor-type tyrosine-protein kinase FLT3 (FLT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quizartinib	DM8Y4JS	Acute myeloid leukaemia	2A60	Approved	[139]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[140]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[141]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[143]
Venetoclax	DM8I94Y	Chronic lymphocytic leukaemia	2A82.0	Approved	[144]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[145]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[146]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[147]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[148]

Drug(s) Affected By Gasdermin-D (GSDMD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[149]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[150]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[151]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[110]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[152]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[153]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[10]
Ropivacaine	DMSPJG2	Anaesthesia	9A78.6	Approved	[154]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[155]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[156]

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[157]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[158]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[159]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[160]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[160]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[161]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[162]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[163]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[164]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[160]

Drug(s) Affected By Hypoxia-inducible factor 1-alpha (HIF1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[165]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[166]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[167]
Triamterene	DM2HU9I	Congestive heart failure	BD10	Approved	[167]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[168]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[169]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[170]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[171]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[172]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aryl hydrocarbon receptor (AHR)	TT037IE	AHR_HUMAN	Modulator	[3]
Fibroblast growth factor receptor 1 (FGFR1)	TTRLW2X	FGFR1_HUMAN	Inhibitor	[4]
Platelet-derived growth factor receptor alpha (PDGFRA)	TT8FYO9	PGFRA_HUMAN	Inhibitor	[5]
Platelet-derived growth factor receptor beta (PDGFRB)	TTI7421	PGFRB_HUMAN	Inhibitor	[5]
Proto-oncogene c-Ret (RET)	TT4DXQT	RET_HUMAN	Inhibitor	[6]
Thrombopoietin receptor (MPL)	TTIHYA4	TPOR_HUMAN	Modulator	[7]
Tyrosine-protein kinase Kit (KIT)	TTX41N9	KIT_HUMAN	Inhibitor	[8]
Vascular endothelial growth factor receptor 2 (KDR)	TTUTJGQ	VGFR2_HUMAN	Inhibitor	[4]
VEGFR1 messenger RNA (VEGFR1 mRNA)	TT1VAUK	VGFR1_HUMAN	Inhibitor	[8]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Gene/Protein Processing	[9]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Gene/Protein Processing	[9]
Gasdermin-D (GSDMD)	OTH39BKI	GSDMD_HUMAN	Gene/Protein Processing	[10]
High mobility group protein B1 (HMGB1)	OT4B7CPF	HMGB1_HUMAN	Gene/Protein Processing	[10]
Hypoxia-inducible factor 1-alpha (HIF1A)	OTADSC03	HIF1A_HUMAN	Gene/Protein Processing	[11]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Protein Interaction/Cellular Processes	[10]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[12]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Gene/Protein Processing	[11]
Receptor-type tyrosine-protein kinase FLT3 (FLT3)	OTMSRYMK	FLT3_HUMAN	Gene/Protein Processing	[13]
Ribosomal protein S6 kinase beta-1 (RPS6KB1)	OTAELNGX	KS6B1_HUMAN	Gene/Protein Processing	[11]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6974).
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5056).
• [3] A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer. 2005 Oct 17;93(8):876-83.
• [4] Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
• [5] Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
• [6] Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96.
• [7] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [8] New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
• [9] TSU-16, (Z)-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone, is a potent activator of aryl hydrocarbon receptor and increases CYP1A1 and CYP1A2 expression in human hepatocytes. Chem Biol Interact. 2010 Apr 15;185(1):33-41.
• [10] Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events. Toxicol In Vitro. 2021 Mar;71:105063. doi: 10.1016/j.tiv.2020.105063. Epub 2020 Dec 1.
• [11] SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochem Biophys Res Commun. 2004 Nov 12;324(2):471-80. doi: 10.1016/j.bbrc.2004.09.082.
• [12] Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
• [13] SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003 Aug 1;102(3):795-801. doi: 10.1182/blood-2002-10-3023. Epub 2003 Mar 20.
• [14] Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
• [15] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722).
• [17] A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis. Blood. 2006 Jun 1;107(11):4300-7.
• [18] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [19] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [20] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215272.
• [21] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [22] Clinical pipeline report, company report or official report of Ikena Oncology.
• [23] ClinicalTrials.gov (NCT04069026) A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer. U.S. National Institutes of Health.
• [24] Clinical pipeline report, company report or official report of Azora Therapeutics
• [25] In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo. Mol Pharmacol. 2014 Nov;86(5):593-608.
• [26] 1'H-Indole-3'-Carbonyl-Thiazole-4-Carboxylic Acid Methyl Ester Blocked Human Glioma Cell Invasion via Aryl Hydrocarbon Receptor's Regulation of Cytoskeletal Contraction. Biomed Res Int. 2020 Oct 3;2020:2616930.
• [27] 6-Formylindolo(3,2-b)carbazole induced aryl hydrocarbon receptor activation prevents intestinal barrier dysfunction through regulation of claudin-2 expression. Chem Biol Interact. 2018 May 25;288:83-90.
• [28] Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor. Mol Pharmacol. 2006 Jun;69(6):1871-8.
• [29] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [30] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [31] Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013 Apr;28(4):899-911.
• [32] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [33] Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
• [34] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808).
• [35] AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012 Apr 15;72(8):2045-56.
• [36] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [37] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029917)
• [38] Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer. 2002 Jun 17;86(12):1864-70.
• [39] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [40] A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604.
• [41] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [42] The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Invest New Drugs.2015 Apr;33(2):300-9.
• [43] Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
• [44] National Cancer Institute Drug Dictionary (drug id 452042).
• [45] Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
• [46] Clinical pipeline report, company report or official report of MedImmune (2011).
• [47] RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
• [48] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [49] Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
• [50] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [51] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [52] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [53] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
• [54] Company report (Neuronova)
• [55] Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51.
• [56] Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
• [57] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [58] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [59] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185).
• [60] Clinical pipeline report, company report or official report of Turning Point Therapeutics.
• [61] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [62] National Cancer Institute Drug Dictionary (drug name Zeteletinib).
• [63] Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1913-9.
• [64] 2011 Pipeline of Sirna Therapeutics.
• [65] The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
• [66] Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3595-9.
• [67] Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and prelimina... Bioorg Med Chem Lett. 2007 Dec 1;17(23):6593-601.
• [68] Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
• [69] Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
• [70] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [71] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [72] Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
• [73] Clinical pipeline report, company report or official report of Exelixis (2011).
• [74] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [75] Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
• [76] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [77] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [78] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [79] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [80] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [81] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [82] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [83] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [84] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [85] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
• [86] In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
• [87] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [88] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [89] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [90] Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
• [91] Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
• [92] Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
• [93] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [94] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [95] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [96] Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
• [97] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [98] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [99] (9)-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J Pharmacol Exp Ther. 2019 Oct;371(1):191-201. doi: 10.1124/jpet.119.260661. Epub 2019 Aug 5.
• [100] Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
• [101] Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
• [102] Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppression. Apoptosis. 2006 Apr;11(4):573-9. doi: 10.1007/s10495-006-4919-3.
• [103] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [104] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [105] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [106] Endoplasmic reticulum stress contributes to arsenic trioxide-induced intrinsic apoptosis in human umbilical and bone marrow mesenchymal stem cells. Environ Toxicol. 2016 Mar;31(3):314-28.
• [107] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [108] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [109] Dihydroartemisinin induces pyroptosis by promoting the AIM2/caspase-3/DFNA5 axis in breast cancer cells. Chem Biol Interact. 2021 May 1;340:109434. doi: 10.1016/j.cbi.2021.109434. Epub 2021 Mar 6.
• [110] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [111] Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood. 2004 Apr 15;103(8):3138-47. doi: 10.1182/blood-2003-05-1543. Epub 2003 Dec 24.
• [112] Antidepressant drug sertraline modulates AMPK-MTOR signaling-mediated autophagy via targeting mitochondrial VDAC1 protein. Autophagy. 2021 Oct;17(10):2783-2799. doi: 10.1080/15548627.2020.1841953. Epub 2020 Nov 9.
• [113] EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One. 2011;6(6):e18691. doi: 10.1371/journal.pone.0018691. Epub 2011 Jun 2.
• [114] Oxidative stress induces parallel autophagy and mitochondria dysfunction in human glioma U251 cells. Toxicol Sci. 2009 Aug;110(2):376-88. doi: 10.1093/toxsci/kfp101. Epub 2009 May 18.
• [115] Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
• [116] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [117] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [118] D-glucosamine down-regulates HIF-1alpha through inhibition of protein translation in DU145 prostate cancer cells. Biochem Biophys Res Commun. 2009 Apr 24;382(1):96-101. doi: 10.1016/j.bbrc.2009.02.129. Epub 2009 Feb 28.
• [119] Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Res. 2003 Nov 15;63(22):7950-8.
• [120] Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. Cell Cycle. 2010 Apr 15;9(8):1629-38. doi: 10.4161/cc.9.8.11487. Epub 2010 Apr 15.
• [121] Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells. Oncogene. 2016 Aug 25;35(34):4518-28. doi: 10.1038/onc.2015.511. Epub 2016 Feb 8.
• [122] Nicotine-induced survival signaling in lung cancer cells is dependent on their p53 status while its down-regulation by curcumin is independent. Mol Cancer. 2010 Aug 20;9:220.
• [123] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [124] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [125] Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway. J Biochem Mol Toxicol. 2023 Jun;37(6):e23328. doi: 10.1002/jbt.23328. Epub 2023 Feb 19.
• [126] Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2015 Mar;35(3):1063-76. doi: 10.1111/liv.12626. Epub 2014 Jul 30.
• [127] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [128] Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
• [129] Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
• [130] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [131] Low dosage of arsenic trioxide (As(2)O(3)) inhibits angiogenesis in epithelial ovarian cancer without cell apoptosis. J Biol Inorg Chem. 2018 Aug;23(6):939-947. doi: 10.1007/s00775-018-1595-z. Epub 2018 Jul 16.
• [132] Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res. 2004 Aug 15;64(16):5617-23. doi: 10.1158/0008-5472.CAN-03-3927.
• [133] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [134] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [135] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [136] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [137] Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. FASEB J. 2006 Oct;20(12):2027-35. doi: 10.1096/fj.05-5404com.
• [138] Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. Mol Cancer Ther. 2009 Jan;8(1):152-9. doi: 10.1158/1535-7163.MCT-08-0553.
• [139] Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3. Arch Toxicol. 2022 Jan;96(1):177-193. doi: 10.1007/s00204-021-03174-1. Epub 2021 Oct 19.
• [140] Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One. 2011;6(9):e25351. doi: 10.1371/journal.pone.0025351. Epub 2011 Sep 28.
• [141] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [142] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [143] Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. Clin Cancer Res. 2006 Nov 15;12(22):6817-25. doi: 10.1158/1078-0432.CCR-06-1354.
• [144] HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia. Curr Issues Mol Biol. 2023 Aug 23;45(9):7011-7026. doi: 10.3390/cimb45090443.
• [145] Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood. 2016 Jun 9;127(23):2890-902. doi: 10.1182/blood-2015-11-683581. Epub 2016 Apr 20.
• [146] Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res. 2010 Feb 15;16(4):1149-58. doi: 10.1158/1078-0432.CCR-09-2416. Epub 2010 Feb 9.
• [147] Neuronal and cardiac toxicity of pharmacological compounds identified through transcriptomic analysis of human pluripotent stem cell-derived embryoid bodies. Toxicol Appl Pharmacol. 2021 Dec 15;433:115792. doi: 10.1016/j.taap.2021.115792. Epub 2021 Nov 3.
• [148] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [149] CBD Promotes Oral Ulcer Healing via Inhibiting CMPK2-Mediated Inflammasome. J Dent Res. 2022 Feb;101(2):206-215. doi: 10.1177/00220345211024528. Epub 2021 Jul 16.
• [150] Hydroquinone triggers pyroptosis and endoplasmic reticulum stress via AhR-regulated oxidative stress in human lymphocytes. Toxicol Lett. 2023 Mar 1;376:39-50. doi: 10.1016/j.toxlet.2023.01.005. Epub 2023 Jan 13.
• [151] Disulfiram inhibits inflammation and fibrosis in a rat unilateral ureteral obstruction model by inhibiting gasdermin D cleavage and pyroptosis. Inflamm Res. 2021 May;70(5):543-552. doi: 10.1007/s00011-021-01457-y. Epub 2021 Apr 13.
• [152] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [153] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [154] Dexmedetomidine protects against Ropivacaine-induced neuronal pyroptosis via the Nrf2/HO-1 pathway. J Toxicol Sci. 2023;48(3):139-148. doi: 10.2131/jts.48.139.
• [155] The role of Caspase-1/GSDMD-mediated pyroptosis in Taxol-induced cell death and a Taxol-resistant phenotype in nasopharyngeal carcinoma regulated by autophagy. Cell Biol Toxicol. 2020 Oct;36(5):437-457. doi: 10.1007/s10565-020-09514-8. Epub 2020 Jan 28.
• [156] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [157] Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
• [158] Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
• [159] Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
• [160] Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
• [161] Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
• [162] Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
• [163] Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
• [164] Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.
• [165] Cannabidiol disrupts apoptosis, autophagy and invasion processes of placental trophoblasts. Arch Toxicol. 2021 Oct;95(10):3393-3406. doi: 10.1007/s00204-021-03122-z. Epub 2021 Jul 24.
• [166] AMP-activated protein kinase activity is required for vanadate-induced hypoxia-inducible factor 1alpha expression in DU145 cells. Carcinogenesis. 2004 Dec;25(12):2497-507. doi: 10.1093/carcin/bgh253. Epub 2004 Aug 5.
• [167] Identification of chemical compounds that induce HIF-1alpha activity. Toxicol Sci. 2009 Nov;112(1):153-63.
• [168] NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. Int J Cancer. 2009 Jan 1;124(1):223-32. doi: 10.1002/ijc.23934.
• [169] Simvastatin stimulates vascular endothelial growth factor production by hypoxia-inducible factor-1alpha upregulation in endothelial cells. J Cardiovasc Pharmacol. 2008 Mar;51(3):267-73. doi: 10.1097/FJC.0b013e3181624b44.
• [170] Epinephrine facilitates the growth of T cell lymphoma by altering cell proliferation, apoptosis, and glucose metabolism. Chem Biol Interact. 2023 Jan 5;369:110278. doi: 10.1016/j.cbi.2022.110278. Epub 2022 Nov 22.
• [171] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [172] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.